LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Krystal Biotech Inc

Cerrado

SectorSalud

153.83 0.03

Resumen

Variación precio

24h

Actual

Mínimo

153.2

Máximo

157.29

Métricas clave

By Trading Economics

Ingresos

2.6M

38M

Ventas

7.9M

96M

P/B

Media del Sector

31.648

35.293

Margen de beneficio

39.914

Empleados

275

EBITDA

1.5M

39M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+29.91% upside

Dividendos

By Dow Jones

Próximas Ganancias

3 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

601M

4.5B

Apertura anterior

153.8

Cierre anterior

153.83

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

185 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Krystal Biotech Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2025, 23:01 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept 2025, 21:59 UTC

Ganancias

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept 2025, 23:39 UTC

Charlas de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept 2025, 21:00 UTC

Ganancias

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept 2025, 18:43 UTC

Charlas de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept 2025, 18:38 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept 2025, 18:20 UTC

Charlas de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept 2025, 18:14 UTC

Charlas de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept 2025, 17:59 UTC

Charlas de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept 2025, 16:51 UTC

Ganancias

Correct: Exor 1H Net Loss -EUR624M

17 sept 2025, 16:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 16:34 UTC

Charlas de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept 2025, 16:25 UTC

Ganancias

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept 2025, 16:23 UTC

Ganancias

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparación entre iguales

Cambio de precio

Krystal Biotech Inc Esperado

Precio Objetivo

By TipRanks

29.91% repunte

Estimación a 12 meses

Media 200.56 USD  29.91%

Máximo 240 USD

Mínimo 166 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Krystal Biotech Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

133.221 / 169.73Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

185 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat